

# Clinical trials of SR123781A

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 thrombosis prevention

| Trial   | Treatments   | Patients  | Trials design and methods                       |
|---|--|---|---|
| <b>SR123781A vs enoxaparin</b>  |  |   |   |
| <b>DRIVE , 2008</b><br>[NCT00338897]<br>n=854/169<br>follow-up: 5-10 days | SR123781A for 5-10 days, doses ranging from 0.25 to 4.0 mg daily for 10 days<br>versus<br>enoxaparin 40 mg | patients undergoing total hip replacement surgery | Parallel groups<br>double blind<br>12 countries |

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>
- pentasaccharide for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q188>
- pentasaccharide for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q396>

## References

### **DRIVE, 2008:**

Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 2008 Apr 15;51:1498-504 [[18402906](#)]